eligibility_summary
Adults >=18 with WHO-defined follicular lymphoma (stage II-IV needing treatment per GELF), ECOG 0-2, measurable disease per Lugano, HBV carriers only if HBV-DNA negative, adequate organ function (bili <=2x ULN, ALT/AST <=2.5x, Cr <=2x), consent. Exclude: CNS lymphoma, molluscum contagiosum, large-cell transformation, HIV+, active HCV, autoimmune cytopenias/bleeding disorders, warfarin/strong CYP3A inhibitors, recent ACS/stroke/surgery, severe COPD, uncontrolled infection, other recent cancers, pregnancy/lactation (neg test/contraception).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in newly diagnosed follicular lymphoma testing zanubrutinib plus obinutuzumab. Zanubrutinib: oral covalent small‑molecule Bruton’s tyrosine kinase (BTK) inhibitor that blocks B‑cell receptor (BCR) signaling, suppressing malignant B‑cell survival/proliferation and downstream NF‑κB/PI3K–AKT pathways. Obinutuzumab: glycoengineered type II humanized anti‑CD20 monoclonal antibody (immunotherapy) that depletes CD20+ B cells via enhanced antibody‑dependent cellular cytotoxicity/phagocytosis (NK cells/macrophages) and direct cell death, with limited complement activation. Targets: CD20 on follicular lymphoma B cells and BTK within BCR pathway. Aim: synergistic B‑cell depletion plus signaling blockade.